GlassScriptPhysician profile
Erica A Cox
NPI 1407015217
$4,552.74
in general payments reported to CMS, 2019-2025
41 companies · $1,600 in 2025
The $1,600 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $683 · 2022: $95.90 · 2023: $791 · 2024: $1,383 · 2025: $1,600.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,773.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,773.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $780.19 | 2023-2025 | |
| Lilly USA, LLC | $695.80 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $663.86 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $230.75 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $181.22 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $165.21 | 2021-2025 | Rexulti |
| Amgen INC. | $156.27 | 2023-2024 | Repatha, Otezla |
| Neurocrine Biosciences, INC. | $125.00 | 2021 | |
| Merck Sharp & Dohme LLC | $113.47 | 2021-2025 | Capvaxive, Gardasil 9, Gardasil |
| Janssen Biotech, INC. | $102.52 | 2021 | |
| Janssen Products, LP | $99.00 | 2021 | |
| Glaxosmithkline, LLC. | $90.41 | 2023-2024 | Trelegy Ellipta, Shingrix |
| Viiv Healthcare Company | $89.72 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $89.19 | 2024-2025 | |
| Horizon Therapeutics Plc | $88.16 | 2021 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $87.79 | 2023 | Adlarity |
| Corcept Therapeutics | $67.54 | 2025 | Korlym |
| Teva Pharmaceuticals USA, INC. | $64.97 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.86 | 2024-2025 | Jardiance |
| Exact Sciences Corporation | $51.26 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Lundbeck LLC | $50.40 | 2025 | Rexulti |
| Axsome Therapeutics, INC. | $48.68 | 2024 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $45.88 | 2024-2025 | Caplyta |
| Abbott Laboratories | $40.73 | 2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $31.03 | 2024-2025 | Veozah |
| Dexcom, INC. | $30.29 | 2024 | Dexcom G6 Transmitter |
| Sanofi Pasteur INC. | $29.67 | 2023 | |
| Sunovion Pharmaceuticals INC. | $28.67 | 2021 | |
| Medtronic, INC. | $24.07 | 2024 | Kyphon Express II Kyphopak Tray |
| Eisai INC. | $23.03 | 2023 | |
| Cipher Pharmaceuticals US LLC | $21.50 | 2025 | Spinosad, Natroba |
| Napo Pharmaceuticals INC | $21.14 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.34 | 2021 | |
| Xeris Pharmaceuticals, INC. | $17.98 | 2023 | Gvoke Hypopen |
| Shield Therapeutics INC | $17.91 | 2025 | |
| Paratek Pharmaceuticals, INC. | $17.34 | 2024 | Nuzyra |
| Sanofi-Aventis U.S. LLC | $16.58 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $16.22 | 2024 | Uptravi, Opsumit |
| Novavax INC | $16.16 | 2023 | Novavax Covid-19 Vaccine, Adjuvanted |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.50 | 2025 | Xifaxan |
| Currax Pharmaceuticals LLC | $14.43 | 2025 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erica Cox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.